Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Depreciation & Amortization (IS) (2020 - 2024)

Historic Depreciation & Amortization (IS) for Innate Pharma (IPHA) over the last 5 years, with Q4 2024 value amounting to $2.1 million.

  • Innate Pharma's Depreciation & Amortization (IS) fell 6110.02% to $2.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $59.2 million, marking a year-over-year decrease of 5256.35%. This contributed to the annual value of $2.1 million for FY2024, which is 6110.02% down from last year.
  • According to the latest figures from Q4 2024, Innate Pharma's Depreciation & Amortization (IS) is $2.1 million, which was down 6110.02% from $5.5 million recorded in Q4 2023.
  • In the past 5 years, Innate Pharma's Depreciation & Amortization (IS) ranged from a high of $67.7 million in Q4 2020 and a low of $2.1 million during Q4 2024
  • Over the past 5 years, Innate Pharma's median Depreciation & Amortization (IS) value was $5.5 million (recorded in 2023), while the average stood at $25.4 million.
  • As far as peak fluctuations go, Innate Pharma's Depreciation & Amortization (IS) crashed by 9223.6% in 2021, and later surged by 78107.74% in 2022.
  • Innate Pharma's Depreciation & Amortization (IS) (Quarter) stood at $67.7 million in 2020, then plummeted by 92.24% to $5.3 million in 2021, then soared by 781.08% to $46.3 million in 2022, then plummeted by 88.18% to $5.5 million in 2023, then tumbled by 61.1% to $2.1 million in 2024.
  • Its Depreciation & Amortization (IS) stands at $2.1 million for Q4 2024, versus $5.5 million for Q4 2023 and $46.3 million for Q4 2022.